HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Study of the 5-HT2 antagonist ritanserin on sleep-walking cycle in the rat.

Abstract
Ritanserin, a 5-HT2 receptor antagonist, was injected intraperitoneally to rats at light onset. It was found that 0.63 mg/kg decreased waking, increased the slow waves characteristic of the first stage of sleep, and decreased paradoxical sleep (PS) during the first four hours. Active waking was further decreased and slow wave stage increased during the following four hours. The number of synchronized and paradoxical sleep phases decreased whereas their duration increased during the first four hours. Ritanserin at 2.5 mg/kg decreased active waking and PS, whereas quite waking and slow wave stage were increased during the first four hours. Quiet waking was increased during the following four hours. It is concluded that serotonin acting on 5 HT2 receptors is actively involved in sleep-waking regulation.
AuthorsS Silhol, L Glin, C Gottesmann
JournalPharmacology, biochemistry, and behavior (Pharmacol Biochem Behav) Vol. 41 Issue 1 Pg. 241-3 (Jan 1992) ISSN: 0091-3057 [Print] United States
PMID1539075 (Publication Type: Journal Article)
Chemical References
  • Serotonin Antagonists
  • Ritanserin
Topics
  • Animals
  • Circadian Rhythm (drug effects)
  • Electroencephalography
  • Male
  • Rats
  • Rats, Inbred Strains
  • Ritanserin (pharmacology)
  • Serotonin Antagonists (pharmacology)
  • Sleep (drug effects)
  • Sleep Stages (drug effects)
  • Sleep, REM (drug effects)
  • Wakefulness (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: